Pieris Pharmaceuticals Inc (PIRS)

NASDAQ
0.982
+0.006(+0.63%)
  • Volume:
    134,037
  • Day's Range:
    0.972 - 1.010
  • 52 wk Range:
    0.924 - 4.076

PIRS Overview

Prev. Close
0.975
Day's Range
0.972-1.01
Revenue
24.12M
Open
0.985
52 wk Range
0.924-4.076
EPS
-0.472
Volume
134,037
Market Cap
72.18M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
162,067
P/E Ratio
-2.14
Beta
1.08
1-Year Change
-69.89%
Shares Outstanding
73,529,412
Next Earnings Date
Mar 21, 2023
What is your sentiment on Pieris Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Pieris Pharmaceuticals Inc News

Pieris Pharmaceuticals Inc Analysis

Pieris Pharmaceuticals Inc Company Profile

Pieris Pharmaceuticals Inc Company Profile

Employees
133

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Read More

Analyst Price Target

Average7.000 (+612.83% Upside)
High7
Low7
Price0.982
No. of Analysts1
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellSellSellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Low at 3.15Last close at 3.26today i will buy 3.95 close of the year?
    0
    • pre market at 3.45. Yesterday close a 3.32
      0
      • Is this stock worth buying at all?
        0
        • Earning today
          0
          • How is this stock in such a slump??
            0
            • Today open 5$
              1
              • 3.37$ isn't good to buy?
                0
                • SHORTING Time! Easy money :)
                  0
                  • Yeah i hesitate, what's your sell and buy objectif ?
                    0
                • hi
                  0
                  • Price target much higher than where its now. Absolute potential buy.
                    0